Ovarian Neoplasms: all 2,759 studies

Page 17 of 28. Open to participants first (736), then studies with results posted, then the rest; newest registration first within each.

• Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & SurvivalStatus unknownNCT04402333
• Effect of Hemp-CBD on Patients With CIPNStatus unknownNCT04398446Phase 2
• First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2bTerminatedNCT04396340Phase 1
• A Study of Niraparib in Patients With Relapsed Ovarian CancerCompletedNCT04392102Phase 2
• OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)WithdrawnNCT04389229Phase 1/2
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04387227Phase 2
• Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04383977Phase 2
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
• SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer CareWithdrawnNCT04368130Not applicable
• Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian CancerStatus unknownNCT04361370Phase 2
• Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian CancerCompletedNCT04360629Not applicable
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompletedNCT04354246Phase 1
• Impact of the COVID-19 Pandemic in Gynecological OncologyCompletedNCT04351139
• Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04348032Phase 2
• Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian CancerStatus unknownNCT04337632Phase 3
• Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate CancersCompletedNCT04330716Not applicable
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin ChemotherapyActive, not recruitingNCT04310826Not applicable
• Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian CancerStatus unknownNCT04300699Not applicable
• Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceRCompletedNCT04295577
• Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant SettingCompletedNCT04284852Phase 2
• HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC)Status unknownNCT04280185Not applicable
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
• ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerTerminatedNCT04267939Phase 1
• NUVOLA TRIAL Open-label Multicentre StudyStatus unknownNCT04261465Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersTerminatedNCT04260802Phase 1/2
• Preoperative Care In Ovarian Cancer PatientsCompletedNCT04260334Not applicable
• Onco-primary Care Networking to Support TEAM-based CareActive, not recruitingNCT04258813Not applicable
• Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their RelativesCompletedNCT04257045
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesTerminatedNCT04244552Phase 1
• A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2
• HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow upCompletedNCT04234243
• A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
• Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer PatientsCompletedNCT04227522Phase 3
• The Application of Real-Time Near-infrared Imaging in Gynecological SurgeryStatus unknownNCT04224467Not applicable
• Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer PatientsCompletedNCT04222465
• Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian CancerStatus unknownNCT04217798Phase 2
• Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging AlgorithmStatus unknownNCT04214782Not applicable
• The DIALOGUE Study: Swiss-Korean Billateral CollaborationCompletedNCT04214210Not applicable
• Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsTerminatedNCT04213794Early Phase 1
• ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsActive, not recruitingNCT04205227Phase 1/2
• Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant ChemotherapyActive, not recruitingNCT04204811Not applicable
• High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral NeuropathyActive, not recruitingNCT04201561Phase 3
• Genetic Mutation in Epithelial Ovarian CancerStatus unknownNCT04191252
• Homologous Recombination Deficiency Status in Epithelial Ovarian CancerStatus unknownNCT04190667
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedNCT04190628Phase 1
• Diagnosing Ovarian Cysts - the DOC StudyCompletedNCT04188652
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionActive, not recruitingNCT04180371Phase 1/2
• Feasibility of Opportunistic Salpingectomy During Non-Gynecologic SurgeryStatus unknownNCT04176484
• Bevacizumab and Tocotrienol in Recurrent Ovarian CancerCompletedNCT04175470Phase 2
• Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic CancersStatus unknownNCT04170712
• A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerActive, not recruitingNCT04169997Phase 3
• Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant ChemotherapyTerminatedNCT04163094Phase 1
• Optical Biopsy in Gynecological SurgeryCompletedNCT04154683Not applicable
• Real-life Data of Olaparib in Relapsed Ovarian Cancers PatientsCompletedNCT04152941
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnNCT04149145Phase 1
• Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer TissuesActive, not recruitingNCT04147494Early Phase 1
• Breast Cancer Risk After Diagnostic Gene SequencingCompletedNCT04145817Not applicable
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
• Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian CancerCompletedNCT04135521
• Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer.CompletedNCT04122937
• The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology StudyCompletedNCT04122235Not applicable
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
• Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian CancerStatus unknownNCT04101760Phase 3
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04095364Phase 3
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2
• Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian CancerCompletedNCT04089189Phase 2
• Adoptive T Cell Therapy in Patients With Recurrent Ovarian CancerStatus unknownNCT04072263Phase 1/2
• Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian CancerStatus unknownNCT04068974Phase 2
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
• Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)Status unknownNCT04055038Phase 2/3
• MOLecular Characterization and Treatment of THYroid Carcinoma on Struma OvariiWithdrawnNCT04053114
• ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility StudyCompletedNCT04051502Early Phase 1
• ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)Active, not recruitingNCT04044859Phase 1
• Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on HemodynamicsCompletedNCT04032600Not applicable
• NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingNCT04024878Phase 1
• Ovarium Cancer Detection by TEP's and ctDNAStatus unknownNCT04022863
• Tri Association in Patient With Advanced Epithelial Ovarian Cancer in RelapseStatus unknownNCT04015739Phase 2
• Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04000295Phase 3
• A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian CancerCompletedNCT03989336Phase 2
• Paclitaxel Therapeutic Drug Monitoring in Cancer PatientsSuspendedNCT03987555
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
• Role of Surgery in Advanced Ovarian CancerCompletedNCT03980028
• PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian CancerActive, not recruitingNCT03965481Not applicable
• Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian CarcinomaCompletedNCT03959761Phase 1/2
• Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian CancerActive, not recruitingNCT03949283Phase 3
• CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsTerminatedNCT03944902Phase 1
• Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1
• Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT03942068Phase 2
• Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)CompletedNCT03940196Phase 3
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerActive, not recruitingNCT03937154Phase 3
• Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerCompletedNCT03936270Phase 2
• Evaluation and Treatment of Iron Deficiency in Ovarian Cancer PatientsTerminatedNCT03933813Phase 1/2
• Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or ChemotherapyWithdrawnNCT03933761Phase 2
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)CompletedNCT03931304
• Anlotinib for Patients With Platinum Resistant or Refractory Ovarian CancerStatus unknownNCT03924882Phase 2
• Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian CancerTerminatedNCT03922776Not applicable
• The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian CancerCompletedNCT03921658

← Ovarian Neoplasms overview